Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for KYV-101 in Myasthenia Gravis. The expected timing is based on the latest available company guidance and may change.
KYSA-6 Study. Share interim Ph2 data at AANEM'25 on October 29, 2025. 10/29/25– Interim data reported. Ph3 enrollment planned by YE 2025. 12/15/25:- Registrational Ph3 trial in generalized myasthenia gravis described as ongoing. 03/05/26:- Updated KYSA-6 Phase 2 data at AAN April 20, 2026. Phase 3 design poster April 21. 03/26/26:- KYSA-6 Phase 3 gMG trial progressing; first patient enrolled December 2025; 14 sites active; AAN April 2026 update reiterated. 04/20/26:- Updated KYSA-6 Ph2 gMG data show durable responses to 52 weeks. Ph3 design poster Apr 21, 2026. 04/21/26:- Updated KYSA-6 Phase 2 gMG data presented at AAN; no new timing disclosed. 05/12/26:- AAN 2026 KYSA-6 Ph2 longer-term data showed durable 1-year responses; additional gMG Ph2 data expected H2 2026. 08/11/26:- KYSA-6 Ph2 topline data expected Q3 2026. Ph3 enrollment completion expected Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.